

Thursday , 11 January 2007

OBJ
LIMITED

RESEARCH PUBLISHED

DERMAPORTATION STUDY TO BE PUBLISHED BY PRESTIGIOUS PEER REVIEW JOURNAL

OBJ Limited (ASX: OBJ) is pleased to announce that Elsevier, the world's leading publisher of peer reviewed science and health information, has notified the Company that the study into Dermaportation enhanced delivery of 5-ALA has been accepted for international publication in the prestigious Journal of Chromatography.

The Journal of Chromatography is a leading publication in the field of drug discovery and provides a scientific forum for the publication of original research on all aspects of fundamental applied science. The scope of the journal includes chromatography, electromigration and other multi-dimensional techniques.

The study titled "Liquid chromatography assay for 5-aminolevulinic acid: application to in vitro assessment of skin penetration via Dermaportation" will be published later in the year through Elsevier, which serves more than 30 million scientists, students, and health and information professionals worldwide. Elsevier has been a leading peer review publication house to the global scientific community for 125 years.

The study, which was conducted at Curtin University in July 2005, showed that Dermaportation increased the rate of transdermal diffusion of the anti-cancer drug 5-aminolevulinic acid or 5-ALA by almost 900% (see Figure 1).




Figure 1: Averaged cumulative amount of 5-ALA as a measure for diffusion is shown for human epidermis treated with dermaportation or passively. The experiment was done in a standard in vitro Franz-type diffusion cell system.

OBJ Limited (ACN 056 482 636)

Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007

Phone: +61 8 9443 3011 Fax: +61 8 9443 3866 Email: jedwards@obj.com.au

OBJ
LIMITED

P
R
E
S
S
R
E
L
E
A
S
E

5-ALA is a topical photodynamic drug traditionally used in the field of scar-less skin cancer treatment. More recently 5-ALA has been used in the treatment of acne and photodamage in cosmetic applications. The ability of Dermaportation to reduce the pre-treatment waiting times to more convenient and practical levels provides potential cost benefits and market acceptance to all sectors of the health care industry.

The study employed donated human female abdominal skin and achieved the greatest improvement over passive diffusion during the important first 30 minutes.

END:

Background to the Announcement

The OBJ Dermaportation technology has been shown to manage and control the transdermal delivery of a broad range of drugs and therapeutic agents ranging from small difficult molecules such as Caffeine, through to large macro-globular proteins drugs such as vaccines.

OBJ's technology has been independently proven in both in-vitro and in-vivo studies and can manage a broader range of molecular sizes, structures and valencies than other active or passive drug delivery systems. OBJ has been successful in managing the through-the-skin delivery of drugs used in the inflammation, pain, cancer and cosmetic fields.

OBJ's technology is low cost, and can be incorporated into reusable drug patches, (as illustrated) disposable single use drug patches and in a range of packaging systems for OTC and retail use.

Sustainable Benefits

Low cost and controlled through-the-skin delivery of drugs, hormones, vitamins, vaccines, anti-bodies and anti-aging molecules has long been the desire of the pharmaceutical industry. It would provide economic, safety and efficacy benefits to the pharmacology, medical, veterinary and cosmetic industries. Side effects could be reduced by localised delivery and programmed delivery rates. Needle stick injuries and needle disposable problems could be eliminated while the reduction in the level of skill required for application could significantly reduce total cost of many health programmes. These clear commercial benefits may only be achievable if the skin's natural barrier effect can be overcome.



OBJ is the first company to create a broad spectrum through-the-skin delivery system that is kind to the skin, completely reversible, yet can handle drugs range from the small difficult molecules up to the largest and most complex proteins and anti-bodies. OBJ manages an extensive IP portfolio and prosecutes patent applications throughout the world.

Independence of Results

OBJ contracts its drug and technology testing programs to independent and respected organisations, such as Western Australian Biomedical Research Institute, Western Australian Institute for Medical Research, Curtin University of Technology and Murdoch University. The high level of independence and international accreditation means that the results attributable to OBJ's proprietary technology can be published and presented at major medical and scientific conferences and forums.

For more information:

Jeffrey Edwards
Phone: +61 8 944 33011
Mobile: 041 791 2211
E-mail: jedwards@obj.com.au